Immunotherapies targeting the PD-1/PD-L1 pathway are now a standard treatment in various malignant tumors, such as melanoma, NSCLC, renal cell carcinoma, Hodgkin’s lymphoma, carcinoma of head and neck, and gastric carcinoma [6–12]. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.